14.10.2023 - Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) was approved by the U.S. Food and Drug Administration (FDA) for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected stage IIB or .
In the Phase 3 CheckMate -76K trial, Opdivo demonstrated a statistically significant improvement in recurrence-free survival compared to placebo1
CheckMate -76K marks the fifth Opdivo-based.
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma¹ streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
In the Phase 3 CheckMate -76K trial, Opdivo demonstrated a statistically significant improvement in recurrence-free survival compared to placebo1CheckMate -76K marks the fifth Opdivo-based indication in earlier stages of cancer, in the U.S.1Opdivo is the only PD-1 inhibitor that is indicated as an adjuvant treatment.
With cancer patients top of mind, teams of Bristol Myers Squibb (NYSE: BMY) employees are celebrating a decade of Coast 2 Coast 4 Cancer (C2C4C) this year and cycling nearly